2021 Volume 70 Issue 3 Pages 566-570
Exchange transfusion (ET) is an effective treatment for severe neonatal jaundice. In this study, we reviewed the cases of infants with ET in Gunma Children’s Medical Center from 2011–2020. Of the total of 56 infants with ETs, 30 with severe neonatal jaundice were identified. Clinical and laboratory data were collected retrospectively from their medical records. Most infants who underwent ET were full term (gestational age 37–41 weeks) (25/30; 83.3%) and were admitted to our hospital after birth (26/30; 86.7%). Out of these 30 infants, 10 were diagnosed as having ABO incompatibility. In eight of these 10 infants, the mothers’ blood group was O and the infants’ blood group was B. Six of these infants (6/10; 60.0%) showed positive results of the direct antiglobulin test. The identified adverse events secondary to ET included thrombocytopenia and others. The majority of adverse events associated with ET were laboratory abnormalities that were asymptomatic. No deaths or complications were reported arising from the treatment.
